At CooperVision, a business unit of CooperCompanies (Nasdaq: COO), we’re driven by a unified purpose of helping people experience life’s beautiful moments. We are connected through our shared values - dedicated, innovative, friendly, partners, and do the right thing. As a leading global manufacturer of contact lenses, we are committed to helping improve the way people see each day. Through our diverse lens portfolio, we tackle the toughest vision challenges – including astigmatism, presbyopia, and childhood myopia. We offer the most complete collection of spherical, toric, and multifocal products available, enabling us to fit 99% of all contact wearers. Learn more at www.coopervision.com.

This role is not eligible for employer-sponsored work authorization now or in the future. Applicants must be authorized to work in the United States on a permanent and ongoing basis without the need for future sponsorship (i.e., H1B, STEM OPT extensions, TN, etc.)
This position requires full-time onsite work (5 days per week) in Victor, NY and is not eligible for relocation assistance

Job Summary:

The Brand Marketing Manager leads the development and execution of portfolio and brand initiatives that contribute to growth across CooperVision's global contact lens portfolio. Working across global and regional marketing teams and cross-functional partners, the role translates consumer-, customer-, and ECP-centric strategies to life through effective commercialization, marketing program execution, and launch support.

The Brand Manager owns defined workstreams within the global brand and portfolio strategy, including positioning, messaging, claims, market intelligence, performance analysis, launch and lifecycle planning, and development of scalable marketing toolkits. The role provides strategic direction to agencies and project partners, evaluates program effectiveness, and recommends actions based on market, customer, competitive, and business performance insights.

This role works collaboratively across Global Marketing, Regional Marketing, Professional Affairs, Clinical Affairs, Regulatory Affairs, Legal, Marketing Communications, and Life Cycle Management teams to ensure executional excellence and stakeholders remain informed of progress, risks, and opportunities. Success requires strong project management, communication, collaboration, and organizational skills, along with a passion for understanding consumer, customer, and ECP needs and translating those insights into effective marketing execution.

4-7 years of progressive brand, product, portfolio, or commercial marketing experience; global or multi-market experience preferred.
Demonstrated ability to manage multiple projects and stakeholders while delivering high-quality work.
Demonstrated ability to use AI-powered tools for research, analysis, presentation creation and marketing development/refinement.
Experience translating customer, consumer, or market insights into marketing activities.
Experience working with research and/or marketing agencies.
Demonstrates learning agility and adaptability, remaining effective in a fast-paced environment with evolving priorities and organizational change.
Proactive communicator who provides timely updates, escalates risks appropriately, and maintains stakeholder alignment.
Strong interpersonal skills with the ability to build trust, credibility, and productive cross-functional relationships.
Analytical mindset with strong data interpretation, problem-solving, and decision-making capabilities.
Proficiency with AI Platforms, Microsoft PowerPoint, Word, Excel, and Outlook. Experience using Salesforce.com and Salesforce Marketing Cloud would be an asset.

For U.S. locations that require disclosure of compensation, the starting base pay for this role is between $121,608 and $162,144 per year and may include cost of living adjustments.The actual base pay includes many factors and is subject to change and modification in the future.This position may also be eligible for other types of compensation and benefits.

We are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender, gender identity or expression, or veteran status. We are proud to be an equal opportunity workplace.

#LI-AK1

Portfolio Marketing & Commercialization

Lead assigned global brand and portfolio workstreams that support business growth, differentiation, and long-range strategic priorities.
Develop and refine brand positioning, messaging, value propositions, claims, and campaign strategies using customer, consumer, professional, market, and competitive insights.
Translate portfolio strategy into clear commercialization plans, market guidance, toolkits, and activation frameworks that can be adapted across regions and countries.
Identify brand and portfolio opportunities, risks, and strategic choices, and develop recommendations for leadership and cross-functional partners.
Champion consistent brand expression and strategic intent while enabling appropriate local market adaptation.

Consumer, Customer & ECP Focus

Build understanding of consumer, customer, and ECP needs, market dynamics, and competitive activity to support marketing strategy and program execution.
Lead and be a competitive intelligence expert, leveraging and synthesizing key activity and insights to enhance marketing effectiveness and commercialization efforts.

Cross-Functional & Regional Partnership

Partner with regional marketing teams and cross-functional stakeholders to support successful execution of global marketing initiatives and product launches.
Lead cross-functional collaboration across Global and Regional Marketing, Professional Affairs, Clinical or Medical Affairs, Regulatory Affairs, Legal, Marketing Communications, Lifecycle Management, Finance, Supply Chain, and other commercial partners.

Marketing Operations & Excellence

Manage global marketing assets, approved claims, and promotional materials to ensure consistency, accessibility, and compliance across markets.
Support project management, business reviews, and operational activities that enable effective execution of portfolio marketing priorities.

Business Contribution

Develop and maintain monthly and quarterly business performance reporting using internal and external data sources.
Track and analyze key performance indicators, identifying trends, risks, and growth opportunities.
Monitor brand and competitive performance, identifying opportunities, risks, and optimization recommendations.
Support annual brand planning, strategic planning, and business review processes.
Prepare management presentations and business updates for leadership and cross-functional teams.

About the company

What CooperSurgical does: CooperSurgical develops and provides products, technologies, and services that support women’s, babies’, and families’ health around the world. How its products work: The company offers a range of reproductive health solutions, including contraception, fertility support, and preventive and therapeutic gynecological care. These products assist clinicians and patients through devices, tests, and therapies designed to aid choice and care in reproductive health. How it differs from competitors: CooperSurgical focuses on a broad set of reproductive health needs—covering contraception, fertility, and gynecologic care—trusted by clinicians worldwide for a wide range of tools and services, which can enable more integrated care compared to providers focused on a narrower segment. Goal: To empower individuals and healthcare professionals to make informed health and life choices and improve care for women, babies, and families globally.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Trumbull, Connecticut

Founded

1990

Get referred to CooperSurgical

See people who can refer or advise you

Simplify's Take

What believers are saying

June 4, 2026 CooperSurgical revenue reached $358 million, up 8% year over year.
September 2026 fertility growth stayed solid at 5%, even amid channel inventory reductions.
Granata Bio's January 15, 2025 Series A+ and obp Surgical acquisition broaden innovation optionality.

What critics are saying

December 2023 IVF recall triggered $271.6 million charges and over 95% claim settlements by June 2026.
September 9, 2026 strategic review retained CooperSurgical after weak offers and competitive IUD pressure.
A future IVF safety failure would damage trust, invite plaintiffs, and threaten franchise survival.

What makes CooperSurgical unique

CooperSurgical owns fertility, labor, and delivery tools across conception-to-birth workflows.
December 11, 2025 direct-sales expansion in France, Italy, Germany, and Spain strengthens clinician access.
Paragard single-hand inserter and Fetal Pillow FDA clearance reinforce differentiated procedural product depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
401(k) Retirement Plan
Parental Leave
Fertility Treatment Support
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options

Company News

Daily Political

Sep 10th, 2026

Cooper Companies (NASDAQ:COO) posts quarterly earnings results, beats expectations by $0.03 EPS.

Cooper Companies (NASDAQ:COO) posts quarterly earnings results, beats expectations by $0.03 EPS. Cooper Companies (NASDAQ:COO - Get Free Report) posted its quarterly earnings results on Wednesday. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.03, Zacks reports. The business had revenue of $1.07 billion during the quarter, compared to analysts' expectations of $1.10 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The business's revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.49 EPS. Cooper Companies updated its Q4 2026 guidance to 1.050-1.090 EPS and its FY 2026 guidance to 4.510-4.550 EPS. Here are the key takeaways from Cooper Companies' conference call: * Strong cash generation and earnings execution: Third-quarter revenue rose 1% organically, non-GAAP EPS increased 4% to $1.15, and free cash flow reached a company-record $273 million. The company repurchased $339 million of shares and increased its authorization by $1 billion. * CooperVision was pressured by deliberate U.S. channel destocking: Revenue was essentially flat, although management said underlying U.S. consumption remained up at a mid-single-digit rate. Similar inventory reductions are expected in the fourth quarter, while legacy hydrogel rationalization and Asia-Pacific challenges will also weigh on results. * The strategic review concluded without a sale of CooperSurgical: The board determined that offers did not adequately reflect the business's long-term value, citing temporary factors including Paragard competition and the fertility litigation settlement. Management said it remains open to future strategic alternatives while prioritizing organic growth and capital returns. * CooperSurgical continued to show solid operating momentum: Organic revenue grew 3%, with fertility revenue up 5% to $141 million, supported by genomics, new clinic wins, and market-share gains. Management remains optimistic about long-term fertility demand and is increasing investment in R&D and new product launches. * Near-term guidance remains subdued: Fourth-quarter organic revenue growth is expected at 0%-2%, with CooperVision down 2% to flat, while additional commercial spending, foreign exchange headwinds, and lower tariff benefits are expected to pressure margins. The scheduled GILTI increase is also expected to raise the fiscal 2027 non-GAAP tax rate to approximately 17.5% from 15.5%. Cooper Companies price performance. Shares of COO opened at $63.48 on Thursday. Cooper Companies has a 1-year low of $58.89 and a 1-year high of $89.83. The stock has a market cap of $12.38 billion, a PE ratio of 53.80, a price-to-earnings-growth ratio of 1.77 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78. The firm has a fifty day moving average price of $72.42 and a 200 day moving average price of $70.02. Cooper Companies declared that its board has approved a share repurchase plan on Wednesday, September 9th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the medical device company to reacquire up to 22.7% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board believes its stock is undervalued. More Cooper Companies news. Here are the key news stories impacting Cooper Companies this week: * CooperCompanies reported fiscal third-quarter adjusted EPS of $1.15, ahead of the $1.11-$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while free cash flow increased 66% to $273 million. * The board expanded its share-repurchase authorization from $2 billion to $3 billion, potentially allowing the company to buy back as much as 22.7% of outstanding shares. Management also repurchased $339.1 million of stock during the quarter, supporting per-share value if executed effectively. * GAAP EPS was $2.24, helped substantially by a $307.2 million discrete tax benefit related to the favorable completion of a U.K. tax examination. This benefit improves reported results but is not representative of recurring operating performance. * CooperCompanies lowered fiscal 2026 adjusted EPS guidance to $4.51-$4.55, below the roughly $4.63 consensus, and set fourth-quarter EPS guidance at $1.05-$1.09 versus expectations near $1.20. Full-year revenue guidance of $4.229-$4.252 billion also implies modest growth. * The strategic review concluded that CooperSurgical will be retained because potential offers were not sufficiently attractive. Investors appear disappointed that the company did not unlock value through a sale, particularly amid fertility-related litigation costs and competitive pressure in the IUD market. Institutional inflows and outflows. A number of hedge funds have recently added to or reduced their stakes in the company. Cresset Asset Management LLC lifted its stake in Cooper Companies by 7.5% in the third quarter. Cresset Asset Management LLC now owns 4,393 shares of the medical device company's stock valued at $301,000 after buying an additional 306 shares during the last quarter. Captrust Financial Advisors grew its position in shares of Cooper Companies by 10.0% during the second quarter. Captrust Financial Advisors now owns 3,500 shares of the medical device company's stock worth $249,000 after acquiring an additional 317 shares during the last quarter. Snowden Capital Advisors LLC grew its position in shares of Cooper Companies by 10.0% during the second quarter. Snowden Capital Advisors LLC now owns 4,088 shares of the medical device company's stock worth $291,000 after acquiring an additional 373 shares during the last quarter. Public Employees Retirement System of Ohio increased its holdings in shares of Cooper Companies by 0.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 62,229 shares of the medical device company's stock valued at $4,266,000 after acquiring an additional 386 shares during the period. Finally, Arkadios Wealth Advisors increased its holdings in shares of Cooper Companies by 14.3% in the 4th quarter. Arkadios Wealth Advisors now owns 3,552 shares of the medical device company's stock valued at $291,000 after acquiring an additional 444 shares during the period. Hedge funds and other institutional investors own 24.39% of the company's stock. Wall street analyst weigh in. Several research analysts recently weighed in on the company. UBS Group started coverage on Cooper Companies in a research report on Tuesday, July 28th. They issued a "neutral" rating and a $75.00 price objective for the company. Citigroup restated a "neutral" rating and issued a $80.00 target price (up from $76.00) on shares of Cooper Companies in a research report on Thursday, August 13th. Robert W. Baird set a $61.00 price target on Cooper Companies in a report on Thursday. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Cooper Companies in a research report on Friday, September 4th. Finally, Piper Sandler cut shares of Cooper Companies from an "overweight" rating to a "neutral" rating and set a $59.00 price target for the company. in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $78.00. Cooper Companies company profile. Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women's health products. Cooper Companies operates through two primary business segments - CooperVision and CooperSurgical - each serving specialized markets within the healthcare industry. The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories. Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Yahoo Finance

Sep 9th, 2026

Cooper Companies tumbles on weak guidance, strategic review conclusion.

Cooper Companies tumbles on weak guidance, strategic review conclusion. Luke Juricic Investing.com - CooperCompanies (NASDAQ:COO) shares plunged 15% in after-hours trading Wednesday after the medical device company reported third-quarter results that missed revenue expectations and issued fourth-quarter and full-year guidance significantly below analyst estimates. The company reported adjusted earnings per share of $1.15 for the fiscal third quarter ended July 31, 2026, beating the analyst consensus of $1.12 by $0.03. However, revenue of $1.07 billion fell short of the $1.1 billion analyst estimate, though it represented a 1% increase YoY. The company also announced it would retain CooperSurgical after completing its strategic review process, concluding that offers received were not in shareholders' best interest. "This quarter included a number of notable developments including earnings exceeding expectations, record free cash flow, solid fertility growth at CooperSurgical, and a favorable completion of a significant tax matter. At CooperVision, however, we reduced U.S. channel inventory that weighed on our results and will continue to impact Q4," said Al White, President and CEO of CooperCompanies. For the fourth quarter of fiscal 2026, the company expects adjusted EPS of $1.05 to $1.09, with the midpoint of $1.07 falling well below the analyst consensus of $1.19. Fourth-quarter revenue is projected at $1.057 billion to $1.080 billion, with the midpoint of $1.069 billion trailing the $1.11 billion consensus estimate. Full-year fiscal 2026 guidance calls for adjusted EPS of $4.51 to $4.55, with the midpoint of $4.53 below the $4.63 consensus. Revenue is expected between $4.229 billion and $4.252 billion, with the midpoint of $4.241 billion under the $4.31 billion estimate. CooperVision revenue of $717.0 million was flat YoY, while CooperSurgical revenue grew 2% to $349.2 million. The company generated free cash flow of $273.0 million, up 66% YoY, and repurchased $339.1 million of common stock during the quarter. The Board expanded its share repurchase authorization from $2 billion to $3 billion.

CooperSurgical

Feb 12th, 2026

CooperSurgical to Launch Direct Sales Model for Labor and Delivery Portfolio in Key European Markets

CooperSurgical to launch direct sales model for Labor and Delivery portfolio in key european markets. TRUMBULL, CT, December 11, 2025, CooperSurgical(R), a leader in women's healthcare and fertility solutions, today announced a strategic shift to a direct sales model for its premier Labor and Delivery products in France, Italy, Germany, and Spain. This transition will forge a closer relationship with healthcare providers, reinforcing the company's commitment to advancing the standard of care for women and babies. Beginning in the company's fiscal first quarter, healthcare providers and healthcare facilities in these markets will gain the ability to procure products directly from CooperSurgical. The portfolio includes the vacuum-assisted delivery products, Fetal Pillow(TM) cephalic elevation device, the INSORB(R) subcuticular skin stapler, and the Lone Star(R) retractor system. This change from a distributor-led model is designed to streamline the customer's ordering process, facilitate easier access to these critical technologies, and provide direct support from CooperSurgical's dedicated customer care center. By creating a direct channel, CooperSurgical aims to better support the clinical community, ensuring that physicians have the resources and guidance needed to implement these innovative solutions effectively. This initiative is central to the company's mission of delivering technologies that support healthier families. About CooperSurgical CooperSurgical is a leading company dedicated to advancing the health of women, babies, and families. The company's portfolio offers effective solutions that support clinical efficiency from conception to delivery. With a history of innovation in the fertility and women's health field, CooperSurgical has pioneered new technologies and continues to drive progress in the industry. Existing Customers - Order directly from CooperSurgical Previously purchased through a distributor? CooperSurgical, Inc. has simplified the process. Its dedicated sales team can assist with product availability, pricing, ordering, and delivery information specific to your country

PR Newswire

Mar 10th, 2025

2025 Inception Fertility Physician Summit Brings Together Thought Leaders, Researchers, And Clinicians From Across The Company To Celebrate Patient Dedication, Collaborate On Research, And Discuss The Future Of Fertility Care

North America's largest provider of fertility services collaborates, celebrates achievements in fertility care including unparalleled patient services. HOUSTON, March 10, 2025 /PRNewswire/ -- Inception Fertility™ (Inception), North America's largest provider of comprehensive fertility services, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024. The Summit brings together team members, including reproductive specialists and clinical managers, from across Inception's vast network of global fertility clinics, The Prelude Network®, to share best practices and resources that make each clinic a leading fertility provider in their respective markets

FinSMEs

Jan 15th, 2025

Granata Bio Secures $15M Series A+ Funding

Granata Bio Corporation, a biopharma company in Boston, MA, raised $15 million in Series A+ funding. Investors included Gedeon Richter, CooperSurgical, and Amboy Street Ventures. The funds will support the company's pipeline and exploration of new assets in reproductive health. Granata Bio has raised over $30 million to date.